Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label study to evaluate the safety and effect on disease progression of triple combination treatment with erlotinib (Tarceva), bevacizumab (Avastin), and capecitabine (Xeloda) in patients with locally advanced and/or metastatic pancreatic cancer (REBECA-Trial)

Next Previous
Trial Profile

An open label study to evaluate the safety and effect on disease progression of triple combination treatment with erlotinib (Tarceva), bevacizumab (Avastin), and capecitabine (Xeloda) in patients with locally advanced and/or metastatic pancreatic cancer (REBECA-Trial)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 12 Jul 2018 Results published in the Investigational New Drugs
  • 23 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 23 May 2013 Planned End Date changed from 1 Dec 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top